| __timestamp | Johnson & Johnson | Merck & Co., Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 21954000000 | 11606000000 |
| Thursday, January 1, 2015 | 21203000000 | 10313000000 |
| Friday, January 1, 2016 | 19945000000 | 9762000000 |
| Sunday, January 1, 2017 | 21420000000 | 9830000000 |
| Monday, January 1, 2018 | 22540000000 | 10102000000 |
| Tuesday, January 1, 2019 | 22178000000 | 10615000000 |
| Wednesday, January 1, 2020 | 22084000000 | 8955000000 |
| Friday, January 1, 2021 | 20118000000 | 9634000000 |
| Saturday, January 1, 2022 | 19046000000 | 10042000000 |
| Sunday, January 1, 2023 | 20112000000 | 10504000000 |
| Monday, January 1, 2024 | 21969000000 |
Cracking the code
In the ever-evolving pharmaceutical industry, understanding spending patterns is crucial for strategic planning. Over the past decade, Johnson & Johnson and Merck & Co., Inc. have demonstrated distinct approaches to their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Johnson & Johnson consistently allocated a higher percentage of their revenue to SG&A, peaking in 2018 with a 12% increase from 2014. In contrast, Merck & Co., Inc. showed a more conservative approach, with a notable dip in 2020, reflecting a 23% decrease from their 2014 spending. This divergence highlights Johnson & Johnson's aggressive market strategies compared to Merck's more cautious fiscal management. As these giants navigate the complexities of the healthcare landscape, their spending patterns offer a window into their strategic priorities and market positioning.
Johnson & Johnson vs Merck & Co., Inc.: Strategic Focus on R&D Spending
Breaking Down SG&A Expenses: Johnson & Johnson vs Alnylam Pharmaceuticals, Inc.
Johnson & Johnson and BioMarin Pharmaceutical Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Exelixis, Inc.
Who Optimizes SG&A Costs Better? Johnson & Johnson or Jazz Pharmaceuticals plc
Comparing SG&A Expenses: Merck & Co., Inc. vs AstraZeneca PLC Trends and Insights
Comparing SG&A Expenses: Merck & Co., Inc. vs Takeda Pharmaceutical Company Limited Trends and Insights
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Verona Pharma plc
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and CymaBay Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Viking Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Celldex Therapeutics, Inc.
Comparing SG&A Expenses: Merck & Co., Inc. vs Xencor, Inc. Trends and Insights